| scholarly article | Q13442814 |
| P50 | author | Antonio Gambardella | Q67725312 |
| Pasquale Comella | Q115614932 | ||
| Bruno Massidda | Q115614944 | ||
| Rossana Casaretti | Q115614946 | ||
| Luigi Maiorino | Q115614948 | ||
| P2093 | author name string | Michele Cannone | |
| Vito Lorusso | |||
| Silvana Leo | |||
| Salvatore Tafuto | |||
| Antonio Farris | |||
| Donato Natale | |||
| P2860 | cites work | “Mini-mental state” | Q25938989 |
| Nonparametric Estimation from Incomplete Observations | Q25938997 | ||
| Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue | Q27863454 | ||
| A new method of classifying prognostic comorbidity in longitudinal studies: development and validation | Q29547376 | ||
| Reporting results of cancer treatment | Q29620070 | ||
| Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials | Q30673291 | ||
| Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors. | Q33342773 | ||
| Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer | Q33347194 | ||
| Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer | Q33810043 | ||
| Should chemotherapy be used as a treatment of advanced colorectal carcinoma (ACC) in patients over 70 years of age? | Q33837320 | ||
| Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer | Q33913953 | ||
| XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer | Q33978749 | ||
| A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. | Q34282412 | ||
| Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study | Q34514696 | ||
| Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study | Q34519158 | ||
| Differential prognostic impact of comorbidity | Q35850854 | ||
| Cancer statistics, 1999. | Q40817780 | ||
| Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer | Q43937160 | ||
| Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer | Q44572711 | ||
| A tailored regimen including capecitabine and oxaliplatin for treating elderly patients with metastatic colorectal carcinoma Southern Italy Cooperative Oncology Group trial 0108. | Q45231756 | ||
| Optimal two-stage designs for phase II clinical trials | Q46412217 | ||
| Pharmacology of antineoplastic agents in older cancer patients | Q73308736 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Italy | Q38 |
| capecitabine | Q420207 | ||
| oxaliplatin | Q422327 | ||
| metastatic colorectal carcinoma | Q108607277 | ||
| P304 | page(s) | 282-289 | |
| P577 | publication date | 2005-07-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108 | |
| P478 | volume | 104 |
| Q30990540 | "Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study. |
| Q33430668 | A phase II study of capecitabine and oxaliplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract |
| Q36661290 | A review of the role of capecitabine in the treatment of colorectal cancer. |
| Q37462241 | Adjuvant therapy for rectal cancer |
| Q35920292 | Capecitabine in the routine first-line treatment of elderly patients with advanced colorectal cancer--results from a non-interventional observation study. |
| Q46965894 | Capecitabine plus oxaliplatin (xelox) in the treatment of chemotherapy-naive patients with metastatic colorectal cancer. |
| Q34639725 | Capecitabine plus oxaliplatin compared with 5-fluorouracil plus oxaliplatin in metastatic colorectal cancer: Meta-analysis of randomized controlled trials |
| Q37085987 | Capecitabine plus oxaliplatin for the treatment of colorectal cancer. |
| Q37154737 | Capecitabine, alone and in combination, in the management of patients with colorectal cancer: a review of the evidence |
| Q37073448 | Colorectal cancer treatment in older patients. |
| Q37073451 | Colorectal cancer treatment in the elderly: tailored therapy approaches |
| Q36598736 | Comparative effectiveness of chemotherapy in elderly patients with metastatic colorectal cancer |
| Q30244769 | Decision-making in geriatric oncology: systemic treatment considerations for older adults with colon cancer |
| Q40888760 | Eastern Canadian Colorectal Cancer Consensus Conference: setting the limits of resectable disease |
| Q46448482 | FOLFOX2 in the treatment of advanced colorectal cancer: a comparison between elderly and middle aged patients |
| Q35863869 | First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study |
| Q36760297 | First-line treatment strategies for elderly patients with metastatic colorectal cancer |
| Q38081864 | Management of advanced colorectal cancer, Part 1. |
| Q36822388 | Oral anticancer drugs in the elderly: an overview |
| Q37242664 | Oxaliplatin-based chemotherapy in the management of colorectal cancer |
| Q43898732 | Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401. |
| Q37230238 | Role of oxaliplatin in the treatment of colorectal cancer |
| Q38216008 | Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer? |
| Q37345922 | Systemic and targeted therapy for advanced colon cancer |
| Q37831218 | The role of peri-operative chemotherapy for resectable colorectal liver metastasis: what does the evidence support? |
| Q36715266 | Tolerance to chemotherapy in elderly patients with cancer |
| Q37427386 | Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer |
| Q37612945 | Treatment of metastatic colorectal cancer in the elderly |
| Q92135044 | Treatment response in elderly patients with advanced colorectal cancer at King Abdulaziz Medical City, Princess Norah Oncology Center, Jeddah |
| Q33370632 | XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer |
| Q37839084 | XELOX in colorectal cancer: a convenient option for the future? |
Search more.